Polarean Imaging PLC Result of AGM (1151F)
July 13 2021 - 8:26AM
UK Regulatory
TIDMPOLX
RNS Number : 1151F
Polarean Imaging PLC
13 July 2021
Polarean Imaging Plc
("Polarean" or the "Company")
Result of AGM
Polarean Imaging plc (AIM: POLX), the medical-imaging technology
company, with an investigational proprietary drug-device
combination product for the magnetic resonance imaging (MRI)
market, announces that at the AGM held earlier today, all
resolutions were duly passed.
Details of the proxy votes received on each resolution by
Polarean's Registrar are set out below:
Resolution For Against
Resolution
1 85,455,493 4,503,288
----------- ----------
Resolution
2 85,433,826 4,513,963
----------- ----------
Resolution
3 92,932,443 10,780
----------- ----------
Resolution
4 92,939,943 10,780
----------- ----------
Resolution
5 92,215,560 735,163
----------- ----------
Resolution
6 92,880,692 63,039
----------- ----------
Resolution
7 84,558,967 5,391,222
----------- ----------
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Via Walbrook PR
Officer
Jonathan Allis, Chairman
Stifel Nicolaus Europe Limited (NOMAD and
Sole Corporate Broker) +44 (0)20 7710 7600
Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare
Investment Banking)
Nick Adams / Fred Walsh (Corporate
Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44
(0)7879 741 001
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue-generating, investigational
drug-device combination companies operating in the high-resolution
medical imaging research space.
The Group develops equipment that enables existing MRI systems
to achieve an improved level of pulmonary function imaging and
specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an
imaging agent to visualise ventilation. (129) Xe gas is currently
being studied for visualisation of gas exchange regionally in the
smallest airways of the lungs, across the alveolar tissue barrier,
and into the pulmonary bloodstream.
In October 2020, the Group submitted a New Drug Application
("NDA") to the FDA for hyperpolarised (129) Xe used to evaluate
pulmonary function and to visualise the lung using MRI. In December
2020, the Group received confirmation of acceptance of its NDA by
the FDA, with a target PDUFA action date of 5 October 2021.
The Group operates in an area of significant unmet medical need
and the Group's technology provides a novel investigational
diagnostic approach, offering a non-invasive and radiation-free
functional imaging platform. The annual burden of pulmonary disease
in the US is estimated to be over US$150 billion.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGSFFFDDEFSEEW
(END) Dow Jones Newswires
July 13, 2021 09:26 ET (13:26 GMT)
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Apr 2024 to May 2024
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From May 2023 to May 2024